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Objective: Microglial phagocytosis of apoptotic cells is an essential component of 
the brain regenerative response during neurodegeneration. Whereas it is very effi-
cient in physiological conditions, it is impaired in mouse and human mesial temporal 
lobe epilepsy, and now we extend our studies to a model of progressive myoclonus 
epilepsy type 1 in mice lacking cystatin B (CSTB).
Methods: We used confocal imaging and stereology-based quantification of apop-
tosis and phagocytosis of the hippocampus of Cstb knockout (KO) mice, an in vitro 
model of phagocytosis and siRNAs to acutely reduce Cstb expression, and a virtual 
three-dimensional (3D) model to analyze the physical relationship between apopto-
sis, phagocytosis, and active hippocampal neurons.
Results: Microglial phagocytosis was impaired in the hippocampus of Cstb KO 
mice at 1 month of age, when seizures arise and hippocampal atrophy begins. This 
impairment was not related to the lack of Cstb in microglia alone, as shown by in 
vitro experiments with microglial Cstb depletion. The phagocytosis impairment was 
also unrelated to seizures, as it was also present in Cstb KO mice at postnatal day 
14, before seizures begin. Importantly, phagocytosis impairment was restricted to 
the granule cell layer and spared the subgranular zone, where there are no active 
neurons. Furthermore, apoptotic cells (both phagocytosed and not phagocytosed) in 
Cstb-deficient mice were at close proximity to active cFos+ neurons, and a virtual 3D 
model demonstrated that the physical relationship between apoptotic cells and cFos+ 
neurons was specific for Cstb KO mice.
Significance: These results suggest a complex crosstalk between apoptosis, phago-
cytosis, and neuronal activity, hinting that local neuronal activity could be related to 
phagocytosis dysfunction in Cstb KO mice. Overall, these data suggest that phago-
cytosis impairment is an early feature of hippocampal damage in epilepsy and opens 
novel therapeutic approaches for epileptic patients based on targeting microglial 
phagocytosis.
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1 |  INTRODUCTION
Progressive myoclonus epilepsy 1 (EPM1) or Unverricht-
Lundborg disease is a genetic neurodegenerative disease 
characterized by disabling myoclonus, epileptic seizures, 
and ataxia. The disease is caused by biallelic loss-of-func-
tion mutations in the cystatin B gene (CSTB) encoding the 
cystatin B protein,1–3 a protease inhibitor that regulates and 
limits the activity of nuclear and cytoplasmic cysteine pro-
teases known as cathepsins.4,5 Cstb knockout (KO) mice 
recapitulate key clinical features of EPM1,5,6 as they de-
velop seizures at 1 month and progressive ataxia at around 
6 months of age,7–10 consistent with findings in humans. 
In addition, Cstb KO mice present early alterations in the 
inflammatory response of microglia, the brain immune 
cells.11–13 In addition to controlling the release of inflam-
matory mediators, microglia are also the brain professional 
macrophages.14 We have recently reported that in both 
mouse and human mesial temporal lobe epilepsy (MTLE), 
microglial phagocytosis of apoptotic cells is impaired,15 
leading us to question whether the phagocytosis impair-
ment would also occur in Cstb KO mice.
Phagocytosis is a highly regulated response that prevents 
the spillover of cytotoxic content that results from the cell 
death, is immunomodulatory, and actively participates in 
maintaining tissue homeostasis.14,16,17 In physiological con-
ditions, microglia are very efficient phagocytes, as their 
processes constantly scan the brain parenchyma and express 
a plethora of receptors for “find-me” and “eat-me” signals 
produced by apoptotic cells.18–21 Microglia are similarly 
efficient facing increased apoptotic cell numbers generated 
during excitotoxicity and inflammation, as they use several 
strategies to cope with increased apoptosis: (1) recruit more 
phagocytic cells, (2) increase the number of apoptotic cells 
phagocytosed per microglial cell, and/or (3) increase the mi-
croglial numbers.15,22 As a consequence, microglial phago-
cytosis is proportional to the number of apoptotic cells, that 
is, microglial phagocytosis is tightly coupled to apoptosis.15 
However, during MTLE the hyperactivity of the neuronal 
network and the massive release of the “find-me” signal ad-
enosine triphosphate (ATP) during seizures interferes with 
the recognition by microglia, resulting in delayed dead cell 
clearance and inflammation.15
To test whether microglial phagocytosis was affected in 
other forms of epilepsy, such as EPM1, we analyzed microglial 
phagocytosis efficiency in Cstb KO mice. Most of the CSTB 
deficiency-related pathological changes have been reported in 
the cerebellum and the cortex,7,9–11 but here we focused on the 
dentate gyrus (DG) of the hippocampus, in whose subgranular 
zone (SGZ) there is ongoing production of newborn neurons 
through adulthood.23 Most of these newborn neurons natu-
rally undergo apoptosis and are immediately phagocytosed 
by microglia, allowing us to establish the baseline phagocy-
tosis efficiency.22,24 We here show DG atrophy and microg-
lial phagocytosis impairment at the age when seizures arise, 
at postnatal day 30 (P30). We then studied whether this effect 
was related to a cell-autonomous effect on microglia, using an 
in vitro model of phagocytosis and siRNA-mediated depletion; 
or was related to altered neuronal function, by studying pre-
symptomatic mice at P14, before seizures arise. We found that 
in the neurogenic region, the SGZ, phagocytosis was spared; in 
contrast, phagocytosis was specifically impaired in the granule 
neuron cell layer. We finally used direct analysis and mathe-
matical modeling to determine that apoptotic cells were in 
close proximity to cFos+, activated neurons, in the absence of 
seizures. Our data suggest a complex environmental signaling 
in Cstb KO mice that results in granule cell layer–specific mi-
croglial phagocytosis impairment and point toward microglia 
as a potential target of novel treatments aimed at reducing neu-
ronal damage in epilepsy patients.
2 |  MATERIALS AND METHODS
Full methods can be found in Appendix S1.
K E Y W O R D S
apoptosis, epilepsy, hippocampus, microglia, phagocytosis, seizures
Key Points
• Microglial phagocytosis of apoptotic cells is im-
paired in the dentate gyrus of young Cstb KO 
mice (postnatal days 14 and 30)
• Cstb deficiency in cultured microglia does not im-
pair phagocytosis
• Phagocytosis deficiency is restricted to the gran-
ule cell layer, whereas the subgranular zone is 
spared
• A virtual 3D model shows that apoptotic cells 
are closer than expected (3  μm) to active cFos+ 
neurons
• Microglial phagocytosis impairment in Cstb KO 
mice is unrelated to seizures but may be related to 
local neuronal activity
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3 |  RESULTS
3.1 | Microglial phagocytosis is uncoupled 
to apoptosis in Cstb KO mice at P30
To determine the apoptosis/phagocytosis dynamics in Cstb 
KO mice, we focused on the hippocampal DG, as the ongo-
ing neurogenesis and the natural apoptosis of newborn cells 
allow us to compare phagocytosis efficiency between con-
trol and KO mice.22 We focused on P30 mice, an age when 
cerebellar apoptosis and cortical atrophy occur and seizures 
begin.7,9 We analyzed the granule cell population by im-
munostaining the DG of both wild-type (WT) and Cstb KO 
mice with the nuclear marker 4,6-diamidino-2-phenylindole 
(DAPI) to assess apoptosis by karyorrhexis and/or pyknosis, 
and with Iba1 to visualize microglia (Figure 1A). We found 
a significant increase in the total number of apoptotic cells 
(Figure 1B) that was translated into a decrease in the total 
granule cell population in Cstb KO mice compared to WT 
mice (Figure  1C). However, the total granule cell density 
was similar in both genotypes, with a trend toward a reduc-
tion in the volume of the septal hippocampus (P  = .052; 
Figure  1D,E). This increased apoptosis and trend toward 
decreased hippocampal volume in Cstb KO mice at P30 are 
consistent with the cerebellar and cortical atrophy previously 
described.9–11
Next, we analyzed microglial phagocytosis by measur-
ing the phagocytic index (Ph index), that is, the percent-
age of apoptotic cells engulfed by microglia. Microglia in 
Cstb KO mice engulfed 16.6 ± 1.2% of the apoptotic cells, 
significantly less than WT mice (84.3 ± 4.1%, P <  .001; 
Figure  1F), suggesting that Cstb KO microglia were al-
tered. To directly test the proportion of microglial cells 
that were engaged in phagocytosis, we analyzed their 
phagocytic capacity (Ph capacity), that is, the number of 
phagocytic pouches containing an apoptotic cell per mi-
croglial cell. Cstb KO mice showed an increased Ph capac-
ity compared to WT mice, with fewer nonphagocytic cells 
and more cells with one phagocytic pouch (Figure 1G,H). 
Microglial numbers were also increased in Cstb KO mice 
compared to WT mice (Figure 1I), leading to an increase 
in net phagocytosis (number of microglia multiplied by the 
Ph capacity). Nonetheless, this increase in net phagocytosis 
was insufficient to compensate for the increase in apop-
tosis, leading to a reduction in the phagocytosis/apoptosis 
coupling (ratio between net phagocytosis and total number 
of apoptotic cells; Figure 1J). Thus, despite the attempt to 
increase microglial numbers and Ph capacity, microglia 
were not able to remove the increasing numbers of dead 
cells in Cstb KO at P30.
As we had observed an increase in the total number of 
microglia (Figure 1I), we then analyzed whether this effect 
was due to microglial proliferation using Ki67, a marker for 
proliferating cells that is expressed during all active phases 
of the cell cycle (Figure 2A,B).25 We observed a significant 
increase in proliferating microglia in Cstb KO mice com-
pared to WT mice at P30 (Figure 2C). In addition, Cstb KO 
microglia presented a hypertrophic morphology (Figures 1A 
and 2A), which was reminiscent of the ameboidlike, mul-
tinucleated phenotype of microglia observed in the kainic 
acid (KA) model of epilepsy.15,26 To assess whether Cstb 
KO microglia also showed multinuclearity, we quantified the 
percentage of cells with more than one nucleus (Figure 1D). 
We found that whereas multinucleated cells were absent in 
control mice, they represented 13.1% ± 1.5% of microglia in 
Cstb KO mice, similar to what we observed 3 days and 7 days 
after KA injection.15
Finally, we addressed whether the impairment in microg-
lial phagocytosis was compensated by recruitment of other 
cell types for phagocytosis. Microglia are specialized phago-
cytic cells; however, other cell types, such as astrocytes, can 
also perform phagocytosis under certain conditions.16 To 
characterize whether astrocytes contributed to the phagocy-
tosis of apoptotic cells, we immunostained the DG for the 
astrocytic marker glial fibrillary acidic protein, as well as 
CD11b for microglia and DAPI for the nuclei (Figure 2E,F). 
We observed a notable morphology change in astrocytes, 
with cells showing thicker processes, in agreement with pre-
viously reported reactive astrogliosis observed in the Cstb 
KO at P30, the onset of myoclonus,11 but no evidence of their 
involvement in phagocytosis. Overall, these results demon-
strate microglial phagocytosis was impaired and not compen-
sated by astrocytes in Cstb KO mice.
3.2 | Cstb knockdown in microglia does not 
alter phagocytosis in vitro
To determine a possible cell-autonomous effect of Cstb on 
microglial phagocytosis, we first addressed whether micro-
glia expressed Cstb in vivo. For this purpose, we used FACS 
(fluorescent activated cell sorting) to purify hippocampal mi-
croglia from fms-EGFP mice (Figure 3A), in which the en-
hanced green fluorescent protein (EGFP) is driven by the fms 
gene, which encodes for the Macrophage Colony Stimulating 
Factor Receptor 1 (MCSF-1),27,28 allowing the discrimination 
of microglia from other cell types. We analyzed the mRNA 
expression of Cstb as well as downstream cathepsins B, L, 
and S by quantitative reverse transcription polymerase chain 
reaction (RT-qPCR), because Cstb mutations are related to 
increased cysteine protease expression29 and activity.30,31 We 
found that Cstb and cathepsins B and L were expressed by 
both microglia and nonmicroglia cells, whereas cathepsin 
S was solely expressed by microglia (Figure 3B). Although 
Cstb was not enriched in microglia compared to other cell 
types, its robust expression suggested that the phagocytosis 
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impairment could be the direct consequence of microglia 
lacking Cstb per se.
To directly assess the effect of microglial Cstb on phago-
cytosis, we set up an in vitro model of Cstb knockdown in the 
microglial cell line BV2 (Figure 3C-I). We transfected BV2 
microglia with 6-carboxyfluorescein–labeled siRNAs against 
Cstb or a scrambled siRNA as a control (Figure 3C). We ob-
tained a high transfection efficiency through a time course of 
6, 24, and 48 hours (Figure 3D) and validated the transcrip-
tion downregulation of the Cstb gene by RT-qPCR through 
the time course. We observed that the expression of Cstb 
was greatly reduced up to 48 hours (Figure 3E), whereas the 
   | 2597SIERRA-TORRE ET Al.
expression of the related cathepsins was not affected by Cstb 
siRNA treatment (Figure 3F). Control and Cstb KO microg-
lia were then fed with apoptotic SHSY5Y-vampire neurons 
for 1 and 4 hours, in which apoptosis was previously induced 
(staurosporine 3 µmol·L–1, 4 hours; Figure 3G).15 Microglia 
were stained with CD11b, apoptotic neurons constitutively ex-
pressed the red fluorescent protein, and nuclei were stained 
with DAPI (Figure 3H). We found no differences in phagocy-
tosis in microglia treated with either scrambled or Cstb siRNA 
(Figure 3I). Our in vitro model, nonetheless, does not fully re-
capitulate the in vivo situation, because Cstb KO mice have 
Cstb chronic depletion that is accompanied by modulation of 
cathepsin activity and/or expression.29,31 Nonetheless, these re-
sults suggest that the cell-autonomous acute Cstb deficiency in 
microglia is not sufficient to induce the phagocytosis impair-
ment observed in vivo. We therefore searched for alternative 
mechanisms to explain the reduced phagocytosis in Cstb KO 
mice. As we had previously shown that seizures interfere with 
phagocytosis in a mouse model of MTLE, our next step was 
to determine whether the phagocytosis blockage was related to 
seizures by analyzing an early developmental stage, P14.
3.3 | Phagocytosis impairment is specific 
to the granule cell layer in Cstb KO mice at P14
At P14, Cstb KO mice are asymptomatic and do not have 
seizures,11 and in agreement we did not observe any changes 
in the number of active neurons, labeled with the immediate 
early gene cFos, whose expression is rapidly induced upon 
depolarization (Figure  4A-C).32 cFos+ neurons were found 
in similar numbers in both WT and Cstb KO mice at P14, 
and they were located exclusively in the granular layer (GL) 
and not in the SGZ, where radial neural stem cells and their 
immature progeny reside (Figure  4A,C). However, we did 
notice that whereas in WT mice most apoptotic cells were 
found in the SGZ, in Cstb KO mice apoptotic cells were 
found mostly in the GL and in very close proximity to cFos+ 
neurons (Figure 4B), prompting us to analyze separately GL 
and SGZ apoptosis and phagocytosis.
In the SGZ, we did not observe any significant difference 
in apoptosis or phagocytosis between WT and Cstb KO mice 
at P14 (Figure 5A-F). In contrast, in the GL there were few 
apoptotic cells in WT mice and a 10-fold increase in Cstb KO 
mice (Figure 5D,E). The majority of these GL apoptotic cells 
were not phagocytosed, resulting in a reduced GL Ph index 
in Cstb KO mice compared to WT mice at P14 (Figure 5F). 
Similar to the global effect we had observed before in the 
whole DG at P30, we found that GL microglia increased 
their Ph capacity in Cstb KO mice compared to WT mice, al-
though this effect was insufficient to cope with the increased 
number of apoptotic cells (Figure 5G,H). In this early stage, 
we found no obvious morphological changes or increases in 
microglial numbers (Figure 5I). Overall, we found that the in-
crease in apoptotic cells was not compensated by a sufficient 
increase in phagocytosis, resulting in an uncoupling between 
apoptosis and phagocytosis (Figure 5J). Overall, these results 
demonstrate that the microglial phagocytosis impairment 
was specific to the GL and preceded seizure development in 
Cstb KO mice at P14. These data suggested that there could 
be functional differences between GL and SGZ that could 
explain the GL-specific increase in apoptosis and microglial 
phagocytosis impairment.
3.4 | Apoptotic cells are in close proximity 
to active cFos+ neurons
The close vicinity of apoptotic cells to GL cFos+ neurons in 
P14 mice (Figure  4B) suggested that the phagocytosis effi-
ciency of GL microglia could be related to neuronal activity, as 
neuronal hyperactivity during seizures prevents microglia from 
targeting apoptotic cells.15 To address whether the proximity 
of cFos+ neurons had an impact on apoptosis and phagocyto-
sis, we directly estimated the distance to each phagocytosed 
and nonphagocytosed cell to the closest cFos+ neuron (nearest 
F I G U R E  1  Microglial phagocytosis is impaired in the dentate gyrus (DG) of postnatal day 30 (P30) Cstb knockout (KO) mice. A, 
Representative confocal images of the DG in wild-type (WT) and Cstb KO P30 mice. Healthy or apoptotic (pyknotic/karyorrhectic) nuclear 
morphology was visualized with 4,6-diamidino-2-phenylindole (DAPI; white), and microglia were stained for Iba1 (cyan). High-magnification 
examples of phagocytic microglia following the typical “ball-and-chain” form (upper right panel), with the tip of their processes or phagocytosing 
with their soma (lower right panel). Arrows point to apoptotic cells engulfed by microglia (Iba1+), and arrowheads point to nonphagocytosed 
apoptotic cells. B, Number of apoptotic cells (pyknotic/karyorrhectic) in the septal hippocampus (sp hippo; n = 6 animals per condition) showing 
both phagocytosed (phago) and nonphagocytosed (non-phago) apoptotic cells. C, Total number of granule cells per septal hippocampus. D, Density 
of granule cells (per mm3) in the septal hippocampus of both WT and Cstb KO P30 mice. E, Proportion (in mm3) between the volume of the septal 
and the temporal portions of the hippocampus in WT and Cstb KO P30 mice. F, Phagocytic index (Ph index; in % of apoptotic cells being engulfed 
by microglia) in the septal hippocampus. G, Weighted phagocytic capacity (Ph capacity) of DG microglia (in parts per unit [ppu]). H, Histogram 
showing the Ph capacity distribution of DG microglia (in % of microglial cells with 0-2 phagocytic pouches [Ph]). I, Number of phagocytic 
(Iba1 + with DAPI inclusions) and nonphagocytic microglial cells (Iba1 + with no DAPI inclusions) per septal hippocampus. J, Phagocytosis/
apoptosis (Ph/A; in fold change) in the septal hippocampus. Bars represent the mean ± standard error of the mean. *P < .05, **P < .01, 
***P < .001, aP = .052 by one-tailed Student t test. Scale bars = 40 µm (A, low magnification), 20 µm (A, high magnification); z-thickness = 7 µm 
(A, low magnification), 3.5 µm (A, high magnification)
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F I G U R E  2  Increased proliferation and multinuclearity in the dentate gyrus (DG) of postnatal day 30 (P30) Cstb knockout (KO) mice. A, DG general 
view of both wild-type (WT) and Cstb KO P30 mice. Proliferating cells were stained for Ki67 (marker for all the active phases of the cell cycle), nuclei 
(4,6-diamidino-2-phenylindole [DAPI]), and microglia (CD11b). B, High-magnification image of proliferating Ki67+ microglia in P30 Cstb KO mice. Arrows 
in A and B point to Ki67+ microglia. C, Percentage of proliferating microglia assessed by the marker Ki67. D, Proportion (in %) between uninucleated and 
multinucleated microglia in the septal hippocampus of WT and Cstb KO P30 mice. E, Representative images of the DG in WT and Cstb KO mice stained for 
DAPI (nuclei), microglia (Iba1), and astrocytes (glial fibrillary acidic protein [GFAP]). F, High-magnification image of an apoptotic cell not phagocytosed 
by either microglia or astrocytes in Cstb KO mice. Bars represent the mean ± standard error of the mean. ***P < .001 by one-tailed Student t test. Scale 
bars = 40 µm (A), 20 µm (B), 40 µm (E), 20 µm (F); z-thickness = 7 μm (A, E), 3.5 μm (B)
F I G U R E  3  Cstb knockdown in microglia does not alter phagocytosis in vitro. A, Experimental design used to isolate microglia (green fluorescent 
protein [GFP]+) from nonmicroglial cells (GFP−) for the hippocampi of 1-month-old mice using flow cytometry and quantitative reverse transcription 
polymerase chain reaction (RT-qPCR) for gene expression analysis. B, Expression of CSTB gene and cathepsins B, L, and S in microglia (GFP+) 
versus nonmicroglial cells (GFP−) in flow-activated cell sorting (FACS)-sorted cells from fms-EGFP mice, in which the promoter of the fms gene, 
encoding for the macrophage colony stimulating factor receptor 1, drives the expression of the enhanced green fluorescent protein mouse hippocampi. 
Ornithine decarboxylase antizyme 1 (OAZ1) was selected as a reference gene. C, Representative confocal images of nontransfected (left panels) and 
scrambled/Cstb siRNA transfected BV2 microglia (middle and right panels). Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI; white), 
BV2 microglia were stained for CD11b (red), and siRNA transfection was assessed by 6-carboxyfluorescein (green) labeling. D, Percentage of 
scrambled/Cstb siRNA transfected cells along a time course (6, 24, and 48 hours). E, RT-qPCR Cstb gene expression in BV2 cells after Cstb siRNA 
silencing through a time course (6, 24, and 48 hours), using OAZ1 as a reference gene. F, RT-qPCR cathepsins B, L, and S gene expression in BV2 cells 
24 hours after siRNA Cstb silencing, using OAZ1 as a reference gene. G, Experimental design of the phagocytosis assay performed 24 hours after BV2 
siRNA transfection. Knockdown BV2 cells are fed for 1 and 4 hours with apoptotic SH-SY5Y vampire neurons. H, Representative confocal images 
of scrambled and Cstb siRNA transfected BV2 cells (CD11b staining, green) fed with apoptotic SH-SY5Y vampire neurons (red) for 1 and 4 hours. 
Arrowheads show phagocytosed SH-SY5Y vampire fragments or full cells. I, Percentage of phagocytic BV2 cells after 1 and 4 hours of phagocytosis. 
Only particles fully enclosed by BV2 pouches were identified as phagocytosis. Bars represent the mean ± standard error of the mean. *P < .05 by two-
way analysis of variance. Scale bars = 60 µm (C), 40 µm (H)
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neighbor [NN]; Figure 6A). Because of the limitation imposed 
by the relatively small thickness of our z-stacks (border effect; 
see Materials and Methods for more detail), we only had a suf-
ficient number of apoptotic cells in KO mice (n = 15 phagocy-
tosed and n = 5 nonphagocytosed apoptotic cells from n = 9 
mice, from an initial set of 295 cells).
In Cstb KO mice, both phagocytosed and nonphagocyto-
sed cells were found very close to the cFos+ NN (3.0 ± 0.5 
and 3.0  ±  0.6  μm, respectively; nonsignificant difference; 
Figure 6B). To determine whether this short distance would 
be expected if cells were homogenously distributed through 
the thickness of our z-stacks, we calculate that 50% of the cells 
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should be located at one-quarter distance to either z-border 
(olive green-shaded area in Figure S1), that is, at 5.9 ± 0.2 
and 6.0 ± 0.1 μm from the cFos+ NN for phagocytosed and 
nonphagocytosed cells, respectively (Figure S1). Thus, both 
phagocytosed and nonphagocytosed apoptotic cells in Cstb 
KO mice seem to be much closer (3 μm) to active neurons 
than would be expected. Although we could not detect signifi-
cant differences between phagocytosed and nonphagocytosed 
cells in Cstb KO mice, these results do suggest an unexpected 
relationship between neuronal activity and apoptosis.
To strengthen the analysis of distance between apoptotic 
cells and NN cFos+ neurons in both WT and KO mice and 
to overcome the limitation of analyzing only 20 cells, we de-
veloped a mathematical model (see Materials and Methods for 
details). We created a virtual three-dimensional (3D) model of 
the GL based on the spatial distribution and density of neurons, 
cFos+ neurons, and apoptotic cells (Figure S1). In this model, we 
reproduced the same experimental limitations imposed by the 
limited thickness of the z-stacks (see Materials and Methods) 
compared to the size of the XY field of view, and therefore no 
cells were discarded due to the border effect. Using this virtual 
3D model, we compared the entire experimental distribution 
of NN distance between cFos+ and apoptotic cells to the dis-
tribution generated by the 10 000 simulations. Specifically, we 
developed four different models (Figure 6C).
In the first model, cFos+ neurons were located in their origi-
nal position (in the z-stack) and the position of the apoptotic cells 
was randomized, and their numbers were extrapolated from the 
experimental cell density (Figure 6C). For each apoptotic cell, 
we performed 10 000 randomizations and calculated the distance 
F I G U R E  4  cFos+ cells in the dentate gyrus (DG) of wild-type (WT) and Cstb knockout (KO) postnatal day 14 (P14) mice. A, Representative 
confocal images of the DG of WT and Cstb KO mice. Healthy or apoptotic (pyknotic/karyorrhectic) nuclear morphology was visualized with 
4,6-diamidino-2-phenylindole (DAPI; white), neurons were identified with the neuronal marker NeuN (green), and activated neurons were stained 
for the early expression gene cFos (magenta). Arrowhead points to an apoptotic cell in the subgranular zone (SGZ) in WT mice; framed apoptotic 
cells in Cstb KO mice are shown in B. Numbered cFos+ cells are shown in C, as cells with high (1, 2), medium-high (3, 4), medium-low (5, 6), and 
low (7,8) cFos intensity. GL, granular layer. (B) High-magnification examples showing the close proximity between apoptotic cells (DAPI, white) 
and cFos+ neurons (magenta) in Cstb KO mice. Granular neurons are stained with NeuN (green). Arrows point to cFos+ neurons. C, Distribution of 
cFos+ cells in WT and Cstb KO mice (per mm3). The color code indicates the classification criteria of the cFos+ cells based on their intensity (high, 
medium-high, medium-low, low). A total of 1046 cells for WT P14 mice and 713 cells for Cstb KO mice were quantified and classified according 
to their cFos expression. No significant differences were found. Scale bars = 50 μm (A), 10 μm (B); z-thickness = 28 µm (A, WT), 17.5 µm (A, KO)
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F I G U R E  5  Phagocytosis impairment is specific to the granule cell layer in Cstb knockout (KO) mice at postnatal day 14 (P14). A, B, Dentate 
gyrus (DG) general view of both wild-type (WT) and Cstb KO P14 mice. Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI; white) and 
microglia with Iba1 (cyan). Closeup images show phagocytosed and nonphagocytosed apoptotic cells in WT and Cstb KO P14 mice. GL, granular 
layer; SGZ, subgranular zone. C, D, Representative images of apoptotic cells (condensed DAPI) engulfed by microglia (M; cyan) in the SGZ of 
WT P14 mice (C) and nonphagocytosed cells in the GL of Cstb KO P14 mice (D). Arrows point to phagocytosed apoptotic cells and arrowheads 
to nonphagocytosed apoptotic cells (A-D). E, Number of apoptotic cells (pyknotic/karyorrhectic) both in the SGZ and GL, per septal hippocampus 
(n = 12 animal for each condition). F, Phagocytic index (Ph index; in % of apoptotic cells being engulfed by microglia) in the SGZ and GL of the 
septal hippocampus in WT and Cstb KO P14 mice. G, Histogram showing the phagocytic capacity (Ph capacity) distribution of DG microglia (in 
% of microglial cells) in the SGZ and GL. H, Weighted Ph capacity of DG microglia (in parts per unit). I, Microglial density (cells/mm3) per septal 
hippocampus in both WT and Cstb KO P14 mice, distinguishing between SGZ and GL. J, Phagocytosis/apoptosis (Ph/A; in fold change) in the 
SGZ and GL of the septal hippocampus in WT and Cstb KO P14 mice. Bars represent the mean ± standard error of the mean. *P < .05, **P < .01, 
***P < .001 by Student t test comparing WT versus KO. ns, not significant. Scale bars = 50 μm (A, B), 5 μm (inserts in A, B), 30 μm (C, D); 
z-thickness = 18.9 µm (A, B), 9.8 µm (C left), 16.1 (C right), 11.2 µm (D left), 12.6 µm (D right). $ means P < .005 comparing GL vs SGL
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F I G U R E  6  Proximal relationship between apoptotic cells and cFos+ neurons in the granule cell layer of Cstb knockout (KO) mice. A, 
Representative confocal images of the granular layer of Cstb KO mice. Healthy or apoptotic (pyknotic/karyorrhectic) nuclear morphology was 
visualized with 4,6-diamidino-2-phenylindole (DAPI; white), neurons were identified with the neuronal marker NeuN (green), microglia (M) 
were identified with Iba1 (cyan), and activated neurons were stained for the early expression gene cFos (magenta). Both phagocytosed (A-Ph) 
and nonphagocytosed apoptotic cells (A) were close to cFos+ neurons (arrows). B, Quantification of distance from phagocytosed (Phago) and 
nonphagocytosed (Non-phago) apoptotic cells to the cFos+ nearest neighbor (NN), for those cells that met the inclusion criteria (see Materials 
and Methods). C, Summary of the different simulation models based on the location and density of cFos+ and apoptotic cells. D, Cumulative 
probability of the distances between apoptotic cells and NN cFos+ neurons for wild-type (WT; blue) and Cstb KO mice (red), resulting from 10 000 
simulations of a virtual three-dimensional (3D) model, indicating the 99% confidence interval (CI). The cumulative probability for real (measured) 
data is shown for WT (dotted blue) and Cstb KO (dotted orange). E, Amplification of the area shown in D. F, Cumulative probabilities of the 
distances between apoptotic cells and NN cFos+ neurons for WT (blue) and Cstb KO mice (red), resulting from 10 000 simulations of the indicated 
virtual 3D model. Scale bars indicate 20 μm. z-thickness = 9.1 µm, 7.7 µm, 16.8 µm, 9.1 µm (A, from left to right)
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to the NN cFos+ cell. Finally, the cumulative probability to en-
counter a cFos+ cell within a given distance from an apoptotic 
cell was computed with its 99% confidence interval in both the 
WT- and KO-derived v3D grids (Figure 6D,E). In WT mice, the 
measured apoptotic-cFos+ NN distance was within the modeled 
confidence interval up to a distance of 22 μm, which matches the 
average z-stack thickness (24.2 ± 0.4 μm) and validates that our 
model is isotropic, that is, does not depend on the orientation and 
therefore is within the range of the z-stack thickness. In contrast, 
in Cstb KO mice the measured percentage of NN cFos+-apop-
totic cells between 17 and 24 μm was significantly higher than 
what was observed in both the WT and Cstb KO models. For 
instance, in the Cstb KO model, 20% of the apoptotic cells were 
found at <20 μm from the cFos+ NN, whereas in the real data 
from Cstb KO mice, 20% of the apoptotic cells were found at 
<16 μm and 35% of the apoptotic cells were found at <20 μm 
(Figure 6E). This data suggested that as in our direct quantifica-
tions (Figure 6B), apoptotic cells were closer than expected to 
active cFos+ neurons in Cstb KO mice.
Nonetheless, the modeled distance was significantly larger 
in KO than in WT mice (Figure 6E). To further understand the 
role of other parameters, specifically cell number or location, 
in the model, we used other three different models (Figure 6C): 
Model 2 to test the impact of cFos+ cell location, Model 3 to test 
cFos+ cell density, and Model 4 to test apoptotic cell density. 
We first tested the effect of cFos+ cell location (Model 2), by 
randomly positioning both cFos+ neurons and apoptotic cells 
(Figure 6F1). In this model, there were no differences between 
the modeled NN distances between WT and KO. Importantly, 
in KO mice the difference between the measured and modeled 
apoptotic-cFos+ NN distance was strongly reduced, although 
it was still significant, with a maximum around 20  μm. The 
reduced difference between the measured and modeled NN 
distance in KO mice in Model 2 suggest that the differences 
between the modeled NN distances in Model 1 originated from 
a differential distribution of cFos+ cells between WT and KO.
We then tested the effect of cFos+ density by creating a 
Model 3 in which cFos+ cells were positioned randomly in the 
v3D grid and their number was estimated from the experimen-
tally measured cFos density rescaled by the number of cells 
in the grid, whereas apoptotic cells were modeled randomly 
as above (Figure 6F2). The results of Model 3 were similar to 
Model 2, with no differences between modeled and measured 
NN distances for WT and KO, suggesting that the number 
of cFos+ cells was not related to the differential effect found 
in Model 1. Finally, we tested the effect of different density 
of apoptotic cells in the WT- and KO-modeled distances in 
Model 4. For this, we went back to use the real distribution 
of cFos+  cells (as in Model 1) and positioned the apoptotic 
cells randomly but with an inverted density: the WT model 
using KO apoptotic cell density and vice versa (Figure 6F3). 
The results of Model 4 were similar to Model 1; the modeled 
NN distance was larger in KO than in WT, and apoptotic cells 
were found closer to active neurons than expected in KO mice. 
Overall, these data suggests that although Cstb KO mice have 
similar cFos+ density and intensity at P14 (Figure 4C) and do 
not yet have seizures,11 they have an abnormal distribution of 
cFos+ active neurons that results in a closer distance to apop-
totic cells (Figure 6B,C). These results suggest a very close 
relationship between abnormal neuronal activity in Cstb KO 
mice and apoptotic cells. Indirectly, they also suggest a rela-
tionship with the phagocytosis impairment found in Ctsb KO 
mice, because the number of apoptotic cells observed is the net 
result between apoptosis induction and phagocytosis removal.
4 |  DISCUSSION
In this paper, we show for the first time that microglial phagocy-
tosis of apoptotic cells is impaired in Cstb KO mice, a model that 
recapitulates the main features of clinical EPM1. Additionally, 
we provide evidence on the possible mechanisms that underlie 
the phagocytic disruption associated with CSTB deficiency, 
based on the following findings. First, microglial phagocytosis 
of apoptotic cells was reduced in the hippocampus of sympto-
matic Cstb KO mice at P30. Second, the cell-autonomous lack 
of Cstb in microglia did not drive phagocytosis impairment, be-
cause Cstb downregulation in pure microglial cultures did not 
alter phagocytosis efficiency. Third, microglial phagocytosis 
impairment was already present in the hippocampus of Cstb 
KO mice at P14, prior to the onset of seizures, suggesting that 
microglial phagocytosis impairment appears at early stages of 
disease and independent of seizures. Fourth, the impairment was 
specific for the GL, whereas the neurogenic niche of the SGZ 
was spared. Fifth, a virtual 3D model of the hippocampal GL 
in young CSTB KO mice (P14) predicted an aberrant distribu-
tion of cFos active neurons that results in a closer distance to 
apoptotic cells. These results suggest that local neuronal activ-
ity may alter apoptosis dynamics in Cstb KO mice, which may 
explain, at least in part, the reported impairment on microglial 
phagocytosis associated with CSTB deficiency. Here, we will 
first discuss the pathological effects of Cstb deficiency in the 
hippocampus, including atrophy, apoptosis, and phagocytosis 
impairment. Then, we will speculate on the impact of the mi-
croglial phagocytosis deficiency for the pathology of epilepsy. 
Finally, we will examine possible mechanisms underlying this 
impairment, including a cell-autonomous effect of Cstb on mi-
croglia and environment-related factors such as seizures and 
local neuronal activity.
4.1 | Early symptomatic Cstb KO mice 
exhibit slight atrophy of the hippocampus
EPM1 is the most common type of progressive myoclonus 
epilepsy, a heterogeneous group of inherited diseases that 
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concur with myoclonus, epilepsy, and progressive neuronal 
degeneration.33 Most EPM1 patients are homozygous for 
a promoter region repeat expansion mutation resulting in 
significantly reduced CSTB expression.34 Patients with 
total lack of CSTB display an early infantile onset rapidly 
progressing encephalopathy.35,36 Progressive loss of brain 
volume affecting cerebellum, cortex, and hippocampus has 
been reported in patients with CSTB mutations5,6,36,37 as 
well as in Cstb KO mice.3,10,11,38 Accordingly, EPM1 pa-
tients have progressive motor deficits and mild cognitive 
impairment.39
Here, we show earlier effects in hippocampal atrophy 
than previously described starting at 2 months of age using 
magnetic resonance imaging.38 We found that at 1 month 
(P30), Cstb KO mice already contained fewer hippocam-
pal granule cells and a tendency to atrophy in the septal 
hippocampus, with no changes in the temporal region. 
Furthermore, we found increased granule neuron apopto-
sis as early as P14. These developmental defects suggest 
that damage associated with CSTB mutations starts earlier 
than previously suggested, with atrophy developing from 
1 to 6 months in cerebellum, cortex, and hippocampus in 
Cstb KO mice.38 However, more subtle effects are found as 
early as P7, when the cerebellum begins to show decreased 
inhibition and enhanced excitation.40 Therefore, it is possi-
ble that, like the hippocampus, cerebellum and cortex also 
experience pathophysiological changes such as apoptosis 
and microglial phagocytosis impairment in the first post-
natal days.
4.2 | Microglial phagocytosis of apoptotic 
cells is impaired in early symptomatic Cstb 
KO mice
In addition to the neuronal damage, other cell types have 
also been involved in the pathology of EPM1. Some of the 
earliest changes pointed toward an altered inflammatory 
response by microglia, the brain resident macrophages.11,13 
Here we focused on another aspect of microglia: their 
phagocytic function. Microglia are very efficient phago-
cytes in the adult hippocampus in physiological conditions, 
where unchallenged microglia rapidly clear the excess 
newborn cells produced in the neurogenic niche,22 actively 
participating in the regulation of neurogenesis.17 After 
stressful stimuli such as inflammation and excitotoxicity, 
microglia use different strategies to enhance phagocytosis 
and match the increased apoptosis levels15: recruiting more 
cells to become phagocytic (theoretically, up to 100%), 
increasing the phagocytic capacity of each microglial cell 
(at least up to seven pouches per cell), and proliferating. 
Combined, these strategies make microglia a very powerful 
phagocyte.
However, the phagocytic potential of microglia was not 
fully summoned in the hippocampus of young adult Cstb 
KO mice, at the age when they start to manifest clinical 
myoclonus (P30). Although microglia tried to compensate 
for increased apoptosis by (1) increasing the number of 
apoptotic cells cleared by each microglial cell and (2) in-
creasing their numbers through proliferation, net phago-
cytosis did not match increased apoptosis in Cstb KO 
mice. These results are in line with previous mouse and 
human data on MTLE, where microglial phagocytosis was 
blocked, leading to accumulation of apoptotic cells in the 
hippocampus.15 Accumulation of apoptotic cells has also 
been observed in the cerebellum as early as 2 months.7 As 
an efficient phagocytosis involves rapid clearance of apop-
totic cells (around 90 minutes in the hippocampus),22 these 
data indirectly suggest microglial phagocytosis dysfunc-
tion in the cerebellum of Cstb KO mice, a hypothesis that 
needs to be tested.
4.3 | Phagocytosis dysfunction in epilepsy
What are the consequences of impaired phagocytosis? 
The most obvious one is the accumulation of apoptotic 
cells. As executor caspases are activated in their cyto-
plasm, when not removed through phagocytosis, apop-
totic cells evolve into secondary necrotic cells.41 Their 
permeable membrane allows the release of toxic intra-
cellular contents and contributes to further damaging 
healthy surrounding neurons, which may further con-
tribute to altering the hippocampal connectivity and to 
cognitive impairment. In addition, phagocytosis is immu-
nomodulatory,15 and in a mouse model of MTLE, phago-
cytosis impairment correlates with the development of 
an inflammatory response.15 In Cstb KO mice, microglia 
exhibited a hypertrophic morphology and multinuclear-
ity, suggestive of microglial dysfunction and inflamma-
tion.15,42 These results are also in agreement with the 
early abnormal morphology and expression of the inflam-
matory protein F4/80 in microglia prior to gross neurode-
generation in Cstb KO mice,11 although the inflammatory 
profile of nonphagocytic microglia needs to be directly 
determined. Inflammation is a common feature of many 
types of epilepsies and epilepsy models, including Cstb 
KO mice.12,13,40 In agreement, inflammatory mediators 
such as interleukin 1 beta potentiate seizures.43,44 Our 
results suggest that in both MTLE15 and EPM1 (here), 
microglial inflammation may arise at least in part due to 
the lack of control resulting from dysfunctional phago-
cytosis. Therefore, developing novel tools to manipulate 
microglial phagocytosis may serve to control secondary 
neuronal damage, inflammation, and their impact on sei-
zures in epilepsy patients.
   | 2605SIERRA-TORRE ET Al.
4.4 | Microglial phagocytosis disruption 
is not due to the cell-autonomous lack of CSTB
The microglial phagocytosis impairment could be mecha-
nistically related to the lack of Cstb in microglia and/or in 
other brain cell types. We here show that Cstb expression 
was not restricted to microglia in the brain, suggesting that 
cell-autonomous (lack of Cstb in microglia) or environ-
ment-driven (lack of Cstb in other cell types) mechanisms 
could underlie the phagocytosis impairment. However, we 
observed no alterations in an in vitro model of phagocyto-
sis using siRNA to deplete microglial Cstb. Nonetheless, 
this in vitro model does not fully recapitulate the full 
extent of CSTB deficiency in EPM1 patients, which in-
cludes a complex modulation of activity and mRNA ex-
pression of target cathepsins of CSTB.38,30 Neither does 
it fully mimic the complexity of in vivo recognition and 
engulfment of apoptotic cells, which requires the release 
of “find-me” signals from apoptotic cells and microglial 
process motility to engulf the cells (whereas in vitro ap-
optotic cells are simply dumped on top of microglia).45 
Despite the model's limitations, these data suggest that the 
lack of Cstb in microglia per se does not impact the clear-
ance of apoptotic cells and suggests that the phagocytosis 
impairment could be related to environmental factors as-
sociated with the lack of Cstb, including its main patho-
logical feature, seizures.
4.5 | Microglial phagocytosis impairment is 
independent of seizure activity
Neuronal hyperactivity during seizures alters the micro-
glial phagocytic response to apoptotic cells. For exam-
ple, seizure-induced widespread release of ATP in MTLE 
masks the microgradients of the “find-me” signal ATP 
used by microglia to find apoptotic cells.15 To analyze 
the impact of seizures in microglial phagocytosis, we 
took advantage of young Cstb KO mice (P14), which 
do not present clinical seizures. Using cFos as a marker 
of neuronal depolarization,32 we did not find significant 
changes in the number of cFos+ neurons but, nonetheless, 
our virtual 3D model indirectly suggested that they were 
abnormally distributed in Cstb KO mice at P14, which is 
likely reflected in the seizures that appear at later stages. 
In addition, it is possible that more subtle alterations 
in the hippocampal circuit are already present at P14. 
Interestingly, cFos active neurons, increased numbers of 
apoptotic cells, and microglial phagocytosis impairment 
were selectively observed in the GL of the hippocampus 
and spared the SGZ, illuminating an unexpected relation-
ship between neuronal activity, cell death, and microglial 
phagocytosis.
4.6 | Local neuronal activity 
in the GL may contribute to the microglial 
phagocytosis impairment
In the GL, apoptotic cells were frequently positioned near 
active neurons labeled with cFos in Cstb KO mice, at an av-
erage distance of 3 μm. In agreement, our virtual 3D model 
suggested that apoptotic cells were located closer to the ac-
tive neurons than would be expected based on their relative 
cell densities. The number of apoptotic cells at a given time 
point is the net result of apoptosis induction (input) minus 
phagocytosis (output), and thus these results indirectly sug-
gest that local neuronal activity in the GL could alter apop-
tosis and phagocytosis dynamics in Cstb KO mice. Neuronal 
activity–dependent molecules such as ATP exert their func-
tions locally due to limited diffusion to short distances in 
the tortuous brain parenchyma.46 For instance, the effective 
diffusivity of a small molecule such as sucrose (0.342 kDa, 
close to the 0.551 kDa of ATP) is 310 μm/s, whereas that of 
larger molecules such as nerve growth factor (26.5 kDa) is 
2.95 μm/s. Therefore, the average 3-μm distance between ap-
optotic cells and active cFos neurons found in Cstb KO mice 
implies that the dead cells are well within the influence area 
of the active neurons' soma. Thus, both the dead cells and 
the reaching microglial processes could be affected by the 
somatic release of modulators by granule neurons, or by the 
perisynaptic release of modulators by incoming fibers from 
several afferent systems.47
The close relationship between apoptotic cells and active 
neurons in Cstb KO mice is supported by both direct measure-
ments and the virtual 3D model but does not provide evidence 
that this relationship affects phagocytosis. Nonetheless, it is 
important to note that the net apoptosis observed is in part the 
result of the phagocytosis dynamics; the number of apoptotic 
cells at any given time depends as much on the input (apopto-
sis induction) as on the output (removal by phagocytosis).14 
Therefore, our data show an overall impairment of microglial 
phagocytosis in the GL of Cstb KO mice and suggest a com-
plex scenario in which subseizure local neuronal activity may 
affect the clearance of apoptotic cells by microglia.
In addition, other pathophysiological mechanisms may 
participate in the phagocytosis impairment observed in Cstb 
KO mice. For instance, one possibility is that intrinsic dif-
ferences between GL and SGZ microglia explain why the 
impairment is restricted to the GL. SGZ microglia are likely 
“trained” for phagocytosis, as they have been exposed to 
apoptotic cells during the postnatal period, whereas GL mi-
croglia are not. This “training” could result in differences 
in their phagocytosis potential. For instance, SGZ microglia 
can reach a Ph capacity around 0.8 parts per unit (ppu) in a 
lipopolysaccharide model at P30.22 This number is very far 
from the 0.18 ppu of GL microglia in Cstb KO mice at P14 
reported here. Microglial subpopulations in the CA region 
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of the hippocampus have been recently observed upon 
seizures induced by pilocarpine, based on the expression 
of keratan sulfate polysaccharides  (epitope 5D4), whose 
overexpression is related to a higher ex vivo phagocytosis 
of zymosan particles possibly related to the engulfment of 
synapses.48 Another potential candidate is the complement 
system, which is used by microglia to facilitate recognition 
(opsonization) of apoptotic cells49 as well as synapses,50 and 
is progressively activated in rodent and human epilepsy,51,52 
including Cstb KO mice.29,40 Nonetheless, it is beyond the 
scope of this paper to test the role of complement or kera-
tan sulfate, and future studies will decipher the underlying 
mechanisms of microglial phagocytosis impairment in Cstb 
KO mice.
In summary, we here extend our initial observations that 
microglial phagocytosis impairment in the hippocampus is 
an early feature of mouse and human MTLE and show that it 
also occurs in a genetic model of EPM1 by Cstb deficiency. 
We also provide an unexpected link between phagocytosis 
impairment, accumulation of apoptotic cells, and local neuro-
nal activity in these mice that further supports the suggestion 
that both abnormal local neuronal activity (in presymptom-
atic Cstb KO mice) and network hyperactivity (in MTLE 
mice) regulate the efficiency of microglial phagocytosis. 
Phagocytosis is an essential component of the brain regen-
erative response, as it removes cell debris and is immuno-
modulatory. Therefore, future therapies for epilepsy patients 
should be aimed not only at reducing neuronal death but also 
at harnessing microglial phagocytosis.
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